November 8, 2021 -- PDS Biotechnology has licensed the tumor-associated and immunologically active T-cell receptor gamma alternate reading frame protein (TARP) from the U.S. National Cancer Institute (NCI).
The worldwide nonexclusive license secures rights for the proprietary TARP antigen from the NCI with patent protection through 2034. TARP is used to treat myeloid leukemia and prostate and breast cancers.
PDS Biotech said it is exploring the effectiveness of its candidate PDS0102, which is made using PDS Biotechnology's Versamune T-cell-activating platform and TARP.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
